Bristol-Myers Ousts Its Chief at Monitor's Urging

By Brooke A. Masters
Washington Post Staff Writer
Wednesday, September 13, 2006

NEW YORK, Sept. 12 -- Drugmaker Bristol-Myers Squibb Co. pushed out its chief executive, Peter R. Dolan, on Tuesday at the urging of a federal monitor who was looking into how top management dealt with generic competition for Plavix, its top-selling heart drug.

Bristol's board announced the departure of Dolan, its chief executive since 2001, and general counsel Richard K. Willard one day after the company's independent directors met with the monitor, Frederick B. Lacey, and Christopher J. Christie, the U.S. attorney for New Jersey.

The New York firm has been operating since last year under a deferred prosecution agreement with Christie that resolved an earlier, unrelated accounting scandal by requiring it to stay out of trouble for two years and allowing Lacey, a former judge, to call for management changes, as he did Monday night.

Bristol Chairman James D. Robinson III said in a conference call that the board unanimously agreed that Dolan had to go. Neither he, Lacey nor Christie would describe specifically what concerned Lacey enough to recommend Dolan's termination.

Although Bristol could have tried to negotiate to keep Dolan, the board chose not to because the Plavix situation and other "failures have caused a loss of confidence," Robinson said. "It was time for a change."

The board temporarily replaced Dolan with James M. Cornelius, a Bristol director and a former chief executive of medical-equipment manufacturer Guidant Corp., where he served in a similar capacity after a scandal there in 2004.

Dolan's ouster is one of the highest-profile management changes at a company operating under a deferred prosecution agreement. Prosecutors often seek new management as part of such settlements -- Bristol named an independent chairman as part of its initial deal -- but subsequent changes are far less common.

Christie's spokesman, Michael Drewniak, said that the U.S. attorney "was fully supportive of Judge Lacey's recommendations" for management change but noted that "there was no finding of a violation of the [agreement] or criminal wrongdoing."

The Plavix issue arose earlier this year after Bristol attempted to strike a deal with Apotex Inc. to keep its competing generic version of the blood-thinning drug off the market until 2011. State attorneys general rejected the deal as anti-competitive, and the Justice Department has opened an antitrust investigation separate from Christie's probe.

Apotex put its product on sale this summer, and it quickly captured 75 percent of the market; Bristol sued for patent infringement and won a preliminary injunction halting further production, but the judge declined to recall the generic medicine already on the market. The case is to be heard in January.

Robinson, Bristol's chairman, said the firm's outside counsel had assured the board Monday night that it had "no reason to believe there was anything unlawful done by anyone at Bristol-Myers Squibb" in connection with the Apotex agreement.

The Plavix dispute is not related to the accounting problems that first got Bristol in trouble. In that case, Bristol was accused of pushing an excess amount of its products on its distributors, a process known as "channel-stuffing." The firm paid $300 million in restitution and agreed to two years of monitoring by Lacey, who has attended board meetings and made quarterly reports to Christie.

CONTINUED     1        >

© 2006 The Washington Post Company